Phenotypes associated with this allele

• Allele Symbol: Pgd^tm1.1Pse
• Allele Name: targeted mutation 1.1, Pankaj Seth
• Allele ID: MGI:6718292
• Summary: 5 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Pgd^tm1.1Pse/Pgd^tm1.1Pse Foxp3^tm9(EGFP/cre/ERT2)Ayr/Foxp3^+	involves: 129S1/Sv * 129X1/SvJ * C57BL/6J	MGI:7657737
cn2	Pgd^tm1.1Pse/Pgd^tm1.1Pse Foxp3^tm4(YFP/icre)Ayr/Foxp3^+	involves: 129S1/Sv * 129X1/SvJ * C57BL/6J	MGI:7657738
cn3	Pgd^tm1.1Pse/Pgd^tm1.1Pse Tg(Cd4-cre)1Cwi/0	involves: C57BL/6 * DBA/2	MGI:6751652
cn4	Pgd^tm1.1Pse/Pgd^tm1.1Pse Tg(Cd4-cre)1Cwi/0 Tg(TcraTcrb)1100Mjb/0	involves: C57BL/6 * DBA/2	MGI:6751655
cn5	Pgd^tm1.1Pse/Pgd^tm1.1Pse Tg(Cd4-cre)1Cwi/0 Tg(TcraTcrb)8Rest/0	involves: C57BL/6 * DBA/2	MGI:6751656

Genotype
MGI:7657737

cn1

• Allelic Composition: Pgd^tm1.1Pse/Pgd^tm1.1Pse; Foxp3^{tm9(EGFP/cre/ERT2)Ayr}/Foxp3⁺
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6J

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

decreased tumor growth/size ( J:313817 )

• injected B16F10 tumor model in tamoxifen-treated mice

Genotype
MGI:7657738

cn2

• Allelic Composition: Pgd^tm1.1Pse/Pgd^tm1.1Pse; Foxp3^{tm4(YFP/icre)Ayr}/Foxp3⁺
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6J

mortality/aging

premature death ( J:313817 )

• shorter than normal lifespans

immune system

enlarged spleen ( J:313817 )

ear inflammation ( J:313817 )

• crusting ears

increased T cell number ( J:313817 )

• increased CD4/CD8 positive in the spleen

• increased frequencies of CD44^high increased CD62L^low effector/memory T cells with reduced CD44^low CD62L^high

abnormal CD4-positive helper T cell morphology ( J:313817 )

• increased Th1, Th2, and Th17 responses.

increased IgA level ( J:313817 )

increased IgD level ( J:313817 )

increased IgE level ( J:313817 )

increased IgG2a level ( J:313817 )

increased IgG3 level ( J:313817 )

increased IgM level ( J:313817 )

abnormal regulatory T cell physiology ( J:313817 )

• reduced Tregs suppressive function

increased circulating interferon-gamma level ( J:313817 )

increased circulating interleukin-17 level ( J:313817 )

increased circulating interleukin-4 level ( J:313817 )

increased circulating interleukin-5 level ( J:313817 )

enlarged lymph nodes ( J:313817 )

increased susceptibility to type I hypersensitivity reaction ( J:313817 )

• significant Th2 (allergic) responses in the lung and spleen with increased collagen deposits

increased interferon-gamma secretion ( J:313817 )

• from CD4+ and CD8+ T cells

blepharitis ( J:313817 )

• crusting eyelids

growth/size/body

decreased body size ( J:313817 )

enlarged spleen ( J:313817 )

homeostasis/metabolism

increased circulating interferon-gamma level ( J:313817 )

increased circulating interleukin-17 level ( J:313817 )

increased circulating interleukin-4 level ( J:313817 )

increased circulating interleukin-5 level ( J:313817 )

hearing/vestibular/ear

ear inflammation ( J:313817 )

• crusting ears

vision/eye

blepharitis ( J:313817 )

• crusting eyelids

hematopoietic system

enlarged spleen ( J:313817 )

increased T cell number ( J:313817 )

• increased CD4/CD8 positive in the spleen

• increased frequencies of CD44^high increased CD62L^low effector/memory T cells with reduced CD44^low CD62L^high

abnormal CD4-positive helper T cell morphology ( J:313817 )

• increased Th1, Th2, and Th17 responses.

increased IgA level ( J:313817 )

increased IgD level ( J:313817 )

increased IgE level ( J:313817 )

increased IgG2a level ( J:313817 )

increased IgG3 level ( J:313817 )

increased IgM level ( J:313817 )

abnormal regulatory T cell physiology ( J:313817 )

• reduced Tregs suppressive function

Genotype
MGI:6751652

cn3

• Allelic Composition: Pgd^tm1.1Pse/Pgd^tm1.1Pse; Tg(Cd4-cre)1Cwi/0
• Genetic Background: involves: C57BL/6 * DBA/2

immune system

abnormal T cell differentiation ( J:306553 )

• activation of CD8+ T cells results in a more robust development of T effector cells

abnormal alpha-beta T cell morphology ( J:306553 )

• CD4+ and CD8+ T cells in the spleen and lymph nodes exhibit an altered immune phenotype, characterized by elevated CD44^high/CD62L^low, KLRG1^high/CD127^low subsets and increased expression of CD69 activation marker

decreased CD4-positive, alpha-beta T cell number ( J:306553 )

• the frequency of CD4+ T cells in the lymph nodes and spleen is reduced

• mice have decreased absolute numbers of CD4+ T cells in secondary lymphoid organs

abnormal CD8-positive, alpha beta T cell morphology ( J:306553 )

• CD8+ T cells have a molecular signature of T effector cells in response to activation with anti-CD3 and anti-CD28 mAbs

• CD8+T cells show a large accumulation of glycogen accompanied by an increase in UDP-glucose, the direct substrate for glycogen synthesis

• activated CD8+ T cells have higher mitochondria number per cell than activated control cells and exhibit altered mitochondria morphology with wider cristae and less tightly organized intermembrane space, a pattern seen in effector T cells

decreased CD8-positive, alpha-beta T cell number ( J:306553 )

• the frequency of CD8+ T cells in the lymph nodes and spleen is reduced

• mice have decreased absolute numbers of CD8+ T cells in secondary lymphoid organs

abnormal CD8-positive, alpha-beta T cell physiology ( J:306553 )

• CD8+ T cells exhibit enhanced glucose uptake capacity

• CD8+ T cells exhibit elevated mitochondrial membrane potential and enhanced mitochondrial respiration

• CD8+ T cells show higher reactive oxygen species (ROS) content and mitochondrial ROS production after stimulation than control cells

• examination of mitochondrial fission proteins indicates that mitochondria fission machinery is hyperactivated in in stimulated CD8+ T cells

• CD8+ T cells show an elevated level of lipid peroxidation after stimulation

hematopoietic system

abnormal T cell differentiation ( J:306553 )

• activation of CD8+ T cells results in a more robust development of T effector cells

abnormal alpha-beta T cell morphology ( J:306553 )

• CD4+ and CD8+ T cells in the spleen and lymph nodes exhibit an altered immune phenotype, characterized by elevated CD44^high/CD62L^low, KLRG1^high/CD127^low subsets and increased expression of CD69 activation marker

decreased CD4-positive, alpha-beta T cell number ( J:306553 )

• the frequency of CD4+ T cells in the lymph nodes and spleen is reduced

• mice have decreased absolute numbers of CD4+ T cells in secondary lymphoid organs

abnormal CD8-positive, alpha beta T cell morphology ( J:306553 )

• CD8+ T cells have a molecular signature of T effector cells in response to activation with anti-CD3 and anti-CD28 mAbs

• CD8+T cells show a large accumulation of glycogen accompanied by an increase in UDP-glucose, the direct substrate for glycogen synthesis

• activated CD8+ T cells have higher mitochondria number per cell than activated control cells and exhibit altered mitochondria morphology with wider cristae and less tightly organized intermembrane space, a pattern seen in effector T cells

decreased CD8-positive, alpha-beta T cell number ( J:306553 )

• the frequency of CD8+ T cells in the lymph nodes and spleen is reduced

• mice have decreased absolute numbers of CD8+ T cells in secondary lymphoid organs

abnormal CD8-positive, alpha-beta T cell physiology ( J:306553 )

• CD8+ T cells exhibit enhanced glucose uptake capacity

• CD8+ T cells exhibit elevated mitochondrial membrane potential and enhanced mitochondrial respiration

• CD8+ T cells show higher reactive oxygen species (ROS) content and mitochondrial ROS production after stimulation than control cells

• examination of mitochondrial fission proteins indicates that mitochondria fission machinery is hyperactivated in in stimulated CD8+ T cells

• CD8+ T cells show an elevated level of lipid peroxidation after stimulation

homeostasis/metabolism

increased glycogen level ( J:306553 )

• CD8+T cells show a large accumulation of glycogen accompanied by an increase in UDP-glucose, the direct substrate for glycogen synthesis

• naive CD8+ T cells stimulated with anti-CD3 and anti-CD28 mAbs and IL-2 show glycogen buildup

Genotype
MGI:6751655

cn4

• Allelic Composition: Pgd^tm1.1Pse/Pgd^tm1.1Pse; Tg(Cd4-cre)1Cwi/0; Tg(TcraTcrb)1100Mjb/0
• Genetic Background: involves: C57BL/6 * DBA/2

immune system

abnormal cytotoxic T cell physiology ( J:306553 )

• CD8+ T cells isolated from mutant mice show higher cytotoxic function when co-cultured with EG7 tumor cells in vitro

• congenic (CD45.1+) mice implanted with EG7 tumor cells followed by adoptive transfer of CD8+ T cells from mutant mice show smaller tumors that recipients of control T cells, indicating that antigen-specific T cells have more potent anti-tumor effector function

• recipients of mutant T cells are able to clear a Listeria monocytogenes-Ova infection more effectively than control mice

hematopoietic system

abnormal cytotoxic T cell physiology ( J:306553 )

• CD8+ T cells isolated from mutant mice show higher cytotoxic function when co-cultured with EG7 tumor cells in vitro

• congenic (CD45.1+) mice implanted with EG7 tumor cells followed by adoptive transfer of CD8+ T cells from mutant mice show smaller tumors that recipients of control T cells, indicating that antigen-specific T cells have more potent anti-tumor effector function

• recipients of mutant T cells are able to clear a Listeria monocytogenes-Ova infection more effectively than control mice

Genotype
MGI:6751656

cn5

• Allelic Composition: Pgd^tm1.1Pse/Pgd^tm1.1Pse; Tg(Cd4-cre)1Cwi/0; Tg(TcraTcrb)8Rest/0
• Genetic Background: involves: C57BL/6 * DBA/2

immune system

abnormal CD8-positive, alpha-beta T cell physiology ( J:306553 )

• CD8+ T cells co-cultured with B16-F10 melanoma cells uptake glucose more effectively than control cells

• adaptive transfer of mutant CD8+ T cells to congenic recipients bearing the B16-F10 melanoma results in smaller tumor growth than in controls

hematopoietic system

abnormal CD8-positive, alpha-beta T cell physiology ( J:306553 )

• CD8+ T cells co-cultured with B16-F10 melanoma cells uptake glucose more effectively than control cells

• adaptive transfer of mutant CD8+ T cells to congenic recipients bearing the B16-F10 melanoma results in smaller tumor growth than in controls